Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503918 | 0.85 | — | — | |
| SCHEMBL16310454 | 0.84 | OPRM1 (0.42) | CYP4F2CYP4A11OPRM1KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL23727034 | 0.82 | OPRM1 (0.41) | CYP4F2CYP4A11OPRM1KDM4EKMT2A | |
| SCHEMBL7370030 | 0.82 | KDM4E (0.40) | CYP4F2CYP4A11OPRM1KDM4EKMT2A | |
| SCHEMBL17150393 | 0.82 | CYP4F2 (0.39) | CYP4F2CYP4A11OPRM1KDM4EKMT2A | |
| SCHEMBL761603 | 0.81 | CYP4F2 (0.61) | CYP4F2CYP4A11KMT2ANPSR1MAPT | |
| SCHEMBL3952155 | 0.81 | CYP4F2 (0.56) | CYP4F2CYP4A11KMT2ANPSR1MAPT | |
| SCHEMBL26667104 | 0.81 | TP53 (0.38) | CYP4F2CYP4A11OPRM1KDM4EKMT2A | |
| SCHEMBL13268736 | 0.81 | OPRM1 (0.50) | OPRM1KDM4EKMT2AMAPTSMYD3 | |
| Hydrochloric Acid SCHEMBL20137680 | 0.79 | OPRM1 (0.49) | OPRM1KDM4EKMT2AMAPTSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| CN-1079466-A | 4-or 5-(sulphur) acylimino-and (inferior sulphur) amidopyridine and pyridine-N-oxide thereof | HOECHST AG (DE) | 1993-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CYP4F2 2882/4885CYP4A11 1621/4885OPRM1 826/4885 |
| US-20090264466-A1 | Certain Chemical Entities, Compositions and Methods | MYLK, MYH2, MYH10 | CYP4F2 2631/4885CYP4A11 1628/4885OPRM1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.